SASemih Can Akıncılar

Semih Can Akıncılar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Semih Can Akıncılar has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Figures 1 - 6 from Long-Range Chromatin Interactions Drive Mutant TERT Promoter Activation

    by Semih Can Akıncılar, Ekta Khattar, Priscilla Li Shan Boon, Bilal Unal, Melissa Jane Fullwood, Vinay Tergaonkar

  • Open Access

    Supplementary Tables 1 - 3 from Long-Range Chromatin Interactions Drive Mutant TERT Promoter Activation

    by Semih Can Akıncılar, Ekta Khattar, Priscilla Li Shan Boon, Bilal Unal, Melissa Jane Fullwood, Vinay Tergaonkar

  • Open Access

    Supplementary Figures 1 - 6 from Long-Range Chromatin Interactions Drive Mutant TERT Promoter Activation

    by Semih Can Akıncılar, Ekta Khattar, Priscilla Li Shan Boon, Bilal Unal, Melissa Jane Fullwood, Vinay Tergaonkar

  • Open Access

    Supplementary Tables 1 - 3 from Long-Range Chromatin Interactions Drive Mutant TERT Promoter Activation

    by Semih Can Akıncılar, Ekta Khattar, Priscilla Li Shan Boon, Bilal Unal, Melissa Jane Fullwood, Vinay Tergaonkar

    Supplementary Table 1. Differential gene expression data list of BLM6 and BLM14 cells (-146C>T vs. -146C) for the genes that were predicted to be off-targets of the guide RNA that has been used for the CRISPR/Cas9 genome engineering. Supplementary Table 2. Table showing list of interacting regions obtained from 4C analysis. 4C was performed in BLM6 and BLM14 cells. Differential interactions were obtained from 4C analysis. List shows the genomic coordinates (column 1-3) and their Refseq identities (column 4) of regions interacting with mutant Tert promoter. Column 5 shows whether the regions were tested by 3C-qPCR assay. Y = Yes, N=No. Column 6 shows whether the region was removed by CRISPR/Cas9 editing in the later part of the study. * mark is named as T-INT1 region. Supplementary Table 3. Primer sequences for ChIP-qPCR, 4C and 3C and RT-qPCR experiments.

  • Top Cited Papers
    Open Access

    Telomere-to-mitochondria signalling by ZBP1 mediates replicative crisis

    by Joe Nassour, Lucia Gutierrez Aguiar, Adriana Correia, Tobias T. Schmidt, Laura Mainz, Sara Przetocka, Candy Haggblom, Nimesha Tadepalle, April Williams, Maxim N. Shokhirev, et al.

    Cancers arise through the accumulation of genetic and epigenetic alterations that enable cells to evade telomere-based proliferative barriers and achieve immortality. One such barrier is replicative crisis—an autophagy-dependent program that eliminates checkpoint-deficient cells with unstable telomeres and other cancer-relevant chromosomal aberrations1,2. However, little is known about the molecular events that regulate the onset of this important tumour-suppressive barrier. Here we identified the innate immune sensor Z-DNA binding protein 1 (ZBP1) as a regulator of the crisis program. A crisis-associated isoform of ZBP1 is induced by the cGAS–STING DNA-sensing pathway, but reaches full activation only when associated with telomeric-repeat-containing RNA (TERRA) transcripts that are synthesized from dysfunctional telomeres. TERRA-bound ZBP1 oligomerizes into filaments on the outer mitochondrial membrane of a subset of mitochondria, where it activates the innate immune adapter protein mitochondrial antiviral-signalling protein (MAVS). We propose that these oligomerization properties of ZBP1 serve as a signal amplification mechanism, where few TERRA–ZBP1 interactions are sufficient to launch a detrimental MAVS-dependent interferon response. Our study reveals a mechanism for telomere-mediated tumour suppression, whereby dysfunctional telomeres activate innate immune responses through mitochondrial TERRA–ZBP1 complexes to eliminate cells destined for neoplastic transformation.


  • Open Access

    Identification of mechanism of cancer-cell-specific reactivation of hTERT offers therapeutic opportunities for blocking telomerase specifically in human colorectal cancer

    by Semih Can Akıncılar, Joelle Yi Heng Chua, Qin Feng Ng, Claire Hian Tzer Chan, Zahra Eslami-S, Kaijing Chen, Joo-Leng Low, Surendar Arumugam, Luay Aswad, Clarinda Chua, et al.

    Transcriptional reactivation of hTERT is the limiting step in tumorigenesis. While mutations in hTERT promoter present in 19% of cancers are recognized as key drivers of hTERT reactivation, mechanisms by which wildtype hTERT (WT-hTERT) promoter is reactivated, in majority of human cancers, remain unknown. Using primary colorectal cancers (CRC) we identified Tert INTeracting region 2 (T-INT2), the critical chromatin region essential for reactivating WT-hTERT promoter in CRCs. Elevated β-catenin and JunD level in CRC facilitates chromatin interaction between hTERT promoter and T-INT2 that is necessary to turn on hTERTexpression. Pharmacological screens uncovered salinomycin, which inhibits JunD mediated hTERT-T-INT2 interaction that is required for the formation of a stable transcription complex on the hTERT promoter. Our results showed for the first time how known CRC alterations, such as APC, lead to WT-hTERT promoter reactivation during stepwise-tumorigenesis and provide a new perspective for developing cancer-specific drugs. Healthy and cancer cells harbor the same DNA sequence, but reactivation of the Human Telomerase Reverse Transcriptase (hTERT) gene is observed only in cancer cells. How does that happen was not known for over three decades of research? This study identifies a specific DNA structure that forms only in cancer cells and brings the necessary molecular machinery into the correct position to activate the hTERT gene. The detailed mechanism of hTERT activation provided in this study will be instrumental in designing cancer cell-specific hTERT inhibitors, especially since all the other ways of inhibiting telomerase failed in the clinic.


  • Open Access

    Genome-wide screens identify specific drivers of mutant hTERT promoters

    by Raghuvaran Shanmugam, Mert Burak Ozturk, Joo-Leng Low, Semih Can Akincilar, Joelle Yi Heng Chua, Matan Thangavelu Thangavelu, Giridharan Periyasamy, Ramanuj DasGupta, Vinay Tergaonkar

    Significance: Mutations in hTERT promoter are seen in over 19% of human cancers, irrespective of the cancer type. Understanding the molecular players that regulate Mut- hTERT promoters may help the design of effective targeting strategies to inhibit telomerase reactivation specifically in cancer cells. Our work uses genome-wide functional screens to identify 30 specific regulators of Mut- hTERT promoters. These candidates identified from the screening serve as an excellent resource to understand how telomerase is reactivated and as targets for making inhibitors to telomerase, a key driver of cancer.


  • Open Access

    NAIL: an evolutionarily conserved lncRNA essential for licensing coordinated activation of p38 and NFκB in colitis

    by Semih Can Akıncılar, Lele Wu, Qin Feng Ng, Joelle Yi Heng Chua, Bilal Unal, Taichi Noda, Wei Hong Jeff Chor, Masahito Ikawa, Vinay Tergaonkar

    Objective: NFκB is the key modulator in inflammatory disorders. However, the key regulators that activate, fine-tune or shut off NFκB activity in inflammatory conditions are poorly understood. In this study, we aim to investigate the roles that NFκB-specific long non-coding RNAs (lncRNAs) play in regulating inflammatory networks. Design: Using the first genetic-screen to identify NFκB-specific lncRNAs, we performed RNA-seq from the p65-/- and Ikkβ -/- mouse embryonic fibroblasts and report the identification of an evolutionary conserved lncRNA designated mNAIL (mice) or hNAIL (human). hNAIL is upregulated in human inflammatory disorders, including UC. We generated mNAILΔNFκB mice, wherein deletion of two NFκB sites in the proximal promoter of mNAIL abolishes its induction, to study its function in colitis. Results: NAIL regulates inflammation via sequestering and inactivating Wip1, a known negative regulator of proinflammatory p38 kinase and NFκB subunit p65. Wip1 inactivation leads to coordinated activation of p38 and covalent modifications of NFκB, essential for its genome-wide occupancy on specific targets. NAIL enables an orchestrated response for p38 and NFκB coactivation that leads to differentiation of precursor cells into immature myeloid cells in bone marrow, recruitment of macrophages to inflamed area and expression of inflammatory genes in colitis. Conclusion: NAIL directly regulates initiation and progression of colitis and its expression is highly correlated with NFκB activity which makes it a perfect candidate to serve as a biomarker and a therapeutic target for IBD and other inflammation-associated diseases.